Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ILLUMINA, INC.ILMN · Entity 3137 | SVP, Entrepreneurial Devlopmt | December 10, 2020 | December 14, 2020 |
| Seer, Inc.SEER · Entity 6717 | Director | June 14, 2023 | June 17, 2023 |
| Senti Biosciences Holdings, Inc.DYNS · Entity 7935 | Director · Chief Executive Officer | May 25, 2021 | May 26, 2021 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ILLUMINA, INC.
Report date December 10, 2020 · Filed December 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 80,162 |
Ending reported balance
After 2020-12-10 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2020-12-10 · Sale · Disposed 1,300 · Balance 83,862 F1: The sale was made pursuant to a 10b5-1 plan. F2: Weighted average sale price representing 1,300 shares sold ranging from $336.2100 to $337.0850 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Row 2 · 2020-12-10 · Sale · Disposed 1,100 · Balance 82,762 F1: The sale was made pursuant to a 10b5-1 plan. F3: Weighted average sale price representing 1,100 shares sold ranging from $337.8000 to $338.4450 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Row 3 · 2020-12-10 · Sale · Disposed 2,200 · Balance 80,562 F1: The sale was made pursuant to a 10b5-1 plan. F4: Weighted average sale price representing 2,200 shares sold ranging from $339.1100 to $339.9900 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Row 4 · 2020-12-10 · Sale · Disposed 400 · Balance 80,162 F1: The sale was made pursuant to a 10b5-1 plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was made pursuant to a 10b5-1 plan.
F2: Weighted average sale price representing 1,300 shares sold ranging from $336.2100 to $337.0850 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
F3: Weighted average sale price representing 1,100 shares sold ranging from $337.8000 to $338.4450 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
F4: Weighted average sale price representing 2,200 shares sold ranging from $339.1100 to $339.9900 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.
Seer, Inc.
Report date June 14, 2023 · Filed June 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 224,903 |
Reported balance
After 2023-06-14 transaction · row 1
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 23,443 · Balance 224,903 F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.33 · Expires 2033-06-14 | Direct | 34,735 |
Reported balance
After 2023-06-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-06-14 · Grant · Acquired 34,735 · Balance 34,735 F6: Shares subject to the option vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 15,157 |
Reported balance
Holding disclosure · report date 2023-06-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,157 F2: The shares are held of record Phi-X Capital, LLC, for which the reporting person serves as a manager. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 76,722 |
Reported balance
Holding disclosure · report date 2023-06-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 76,722 F3: The shares are held of record by First Republic Trust Company of Delaware LLC, trustee of a dynasty trust for the reporting person's minor daughter and for which the reporting person serves as an investment advisor. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 76,722 |
Reported balance
Holding disclosure · report date 2023-06-14 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 76,722 F4: The shares are held of record by First Republic Trust Company of Delaware LLC, trustee of a dynasty trust for the reporting person's minor son and for which the reporting person serves as an investment advisor. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 76,722 |
Reported balance
Holding disclosure · report date 2023-06-14 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 76,722 F5: The shares are held of record by The Ronaghi Children's Trust UTD December 2014 for which the reporting person serves as a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
F2: The shares are held of record Phi-X Capital, LLC, for which the reporting person serves as a manager.
F3: The shares are held of record by First Republic Trust Company of Delaware LLC, trustee of a dynasty trust for the reporting person's minor daughter and for which the reporting person serves as an investment advisor.
F4: The shares are held of record by First Republic Trust Company of Delaware LLC, trustee of a dynasty trust for the reporting person's minor son and for which the reporting person serves as an investment advisor.
F5: The shares are held of record by The Ronaghi Children's Trust UTD December 2014 for which the reporting person serves as a trustee.
F6: Shares subject to the option vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
Senti Biosciences Holdings, Inc.
Report date May 25, 2021 · Filed May 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | IndirectSee footnote | 715,500 |
Reported balance
Holding disclosure · report date 2021-05-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 715,500 F1: Up to 60,000 of these shares of Class A common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Issuer's prospectus on Form S-1 filed on May 7, 2021 (the "Prospectus"). F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein. |
| Class B common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2021-05-25 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: These shares of Class B common stock will automatically convert on a one-for-one basis (subject to adjustment) into Class A common stock for no additional consideration at the time of the initial business combination by the Issuer, subject to the adjustments described in the Prospectus. The shares of Class B Common Stock have no expiration date. F4: Up to 750,000 of these shares of Class B common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Prospectus. F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Up to 60,000 of these shares of Class A common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Issuer's prospectus on Form S-1 filed on May 7, 2021 (the "Prospectus").
F2: Dynamics Sponsor LLC, a Delaware limited liability company, (the "Sponsor") is the record holder of these shares. The Sponsor is governed by a board of managers consisting of Omid Farokhzad and Mostafa Ronaghi who hold an economic interest therein.
F3: These shares of Class B common stock will automatically convert on a one-for-one basis (subject to adjustment) into Class A common stock for no additional consideration at the time of the initial business combination by the Issuer, subject to the adjustments described in the Prospectus. The shares of Class B Common Stock have no expiration date.
F4: Up to 750,000 of these shares of Class B common stock will be forfeited in the event the underwriters for the Issuer's initial public offering do not exercise in full their overallotment option in connection with that offering, all as described in the Prospectus.
Summit Therapeutics Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.52 · Expires 2036-01-02 | Direct | 35,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 35,000 · Balance 35,000 F2: Not applicable. F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date.
F2: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2017 Filed Jun 19, 2019 23:07 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 201 | $174.33 | $35,040.33 |
DisclosureSEC source: 0001127602-19-022310 · form4.xml · nonDerivative · entry 2 Ronaghi Mostafa · CIK 0001441876 · SVP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,793 Read SEC document |
| March 03, 2017 Filed Jun 19, 2019 23:07 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GiftCommon Stock | 591 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022310 · form4.xml · nonDerivative · entry 1 Ronaghi Mostafa · CIK 0001441876 · SVP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,994 Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:45 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 7,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007122 · form4.xml · derivative · entry 4 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,032 shares Expires 2017-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on Jan. 29, 2014. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on Jan. 29, 2014. F1 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on Jan. 29, 2014. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:45 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 4,853 | $163.29 | $792,446.37 |
DisclosureSEC source: 0001127602-17-007122 · form4.xml · nonDerivative · entry 3 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,585 F3 · balance_after: Balance includes 144 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:45 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007122 · form4.xml · nonDerivative · entry 2 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,438 F2 · shares: Represents additional shares of stock awarded as a result of the Company achieving at least 150% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on Jan. 29, 2014. Read SEC document |
| February 15, 2017 Filed Feb 18, 2017 01:45 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 7,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007122 · form4.xml · nonDerivative · entry 1 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on Jan. 29, 2014. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 00:36 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 671 | $159.28 | $106,876.88 |
DisclosureSEC source: 0001127602-17-003226 · form4.xml · nonDerivative · entry 1 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,746 Read SEC document |
| December 02, 2016 Filed Dec 7, 2016 01:19 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 11,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-069353 · form4.xml · derivative · entry 2 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,728 Underlying: Common Stock · 11,728 shares Expires 2019-12-29 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2019. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 29, 2019, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F2 · shares: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2019. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 29, 2019, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2019. The number of shares issued will range from 0% to 150% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 29, 2019, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| December 02, 2016 Filed Dec 7, 2016 01:19 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 3,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-16-069353 · form4.xml · nonDerivative · entry 1 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,417 F1 · shares: Grant of restricted stock units that vest as follows: 25% of the shares subject to the award become vested on November 5, 2017, November 5, 2018, November 5, 2019, and November 5, 2020, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 01:37 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 440 | $137.08 | $60,315.20 |
DisclosureSEC source: 0001127602-16-066470 · form4.xml · nonDerivative · entry 1 Ronaghi Mostafa · CIK 0001441876 · Sr VP & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,507 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.